Stelios Papadopoulos - Net Worth and Insider Trading

Stelios Papadopoulos Net Worth

The estimated net worth of Stelios Papadopoulos is at least $51 Million dollars as of 2025-04-26. Stelios Papadopoulos is the Director of Exelixis Inc and owns about 1,260,578 shares of Exelixis Inc (EXEL) stock worth over $47 Million. Stelios Papadopoulos is the Director of Biogen Inc and owns about 26,580 shares of Biogen Inc (BIIB) stock worth over $3 Million. Stelios Papadopoulos is also the Director of Regulus Therapeutics Inc and owns about 118,987 shares of Regulus Therapeutics Inc (RGLS) stock worth over $328,404. Details can be seen in Stelios Papadopoulos's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Stelios Papadopoulos has not made any transactions after 2024-05-20 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

Transaction Summary of Stelios Papadopoulos

Stelios Papadopoulos Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Stelios Papadopoulos owns 7 companies in total, including Regulus Therapeutics Inc (RGLS) , Biogen Inc (BIIB) , and Exelixis Inc (EXEL) among others .

Click here to see the complete history of Stelios Papadopoulos’s form 4 insider trades.

Insider Ownership Summary of Stelios Papadopoulos

Ticker	Company	Transaction Date	Type of Owner
RGLS	Regulus Therapeutics Inc	2019-05-07	director
BIIB	Biogen Inc	2015-07-27	director
EXEL	Exelixis Inc	2024-05-20	director
		2015-11-18	director
		2006-06-22	director
		2020-10-23	director & 10 percent owner
		2020-10-23	director & 10 percent owner

Stelios Papadopoulos Latest Holdings Summary

Stelios Papadopoulos currently owns a total of 3 stocks. Among these stocks, Stelios Papadopoulos owns 1,260,578 shares of Exelixis Inc (EXEL) as of May 20, 2024, with a value of $47 Million and a weighting of 93.12%. Stelios Papadopoulos owns 26,580 shares of Biogen Inc (BIIB) as of July 27, 2015, with a value of $3 Million and a weighting of 6.23%. Stelios Papadopoulos also owns 118,987 shares of Regulus Therapeutics Inc (RGLS) as of May 7, 2019, with a value of $328,404 and a weighting of 0.65%.

Latest Holdings of Stelios Papadopoulos

Ticker	Company	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
EXEL	Exelixis Inc	2024-05-20	1,260,578	37.43	47,183,435
BIIB	Biogen Inc	2015-07-27	26,580	118.84	3,158,767
RGLS	Regulus Therapeutics Inc	2019-05-07	118,987	2.76	328,404

Holding Weightings of Stelios Papadopoulos

Stelios Papadopoulos Form 4 Trading Tracker

According to the SEC Form 4 filings, Stelios Papadopoulos has made a total of 4 transactions in Exelixis Inc (EXEL) over the past 5 years, including 0 buys and 4 sells. The most-recent trade in Exelixis Inc is the sale of 11,437 shares on May 20, 2024, which brought Stelios Papadopoulos around $240,177.

According to the SEC Form 4 filings, Stelios Papadopoulos has made a total of 0 transactions in Biogen Inc (BIIB) over the past 5 years. The most-recent trade in Biogen Inc is the acquisition of 10,000 shares on July 27, 2015, which cost Stelios Papadopoulos around $3 Million.

According to the SEC Form 4 filings, Stelios Papadopoulos has made a total of 0 transactions in Regulus Therapeutics Inc (RGLS) over the past 5 years. The most-recent trade in Regulus Therapeutics Inc is the acquisition of 37,037 shares on May 7, 2019, which cost Stelios Papadopoulos around $400,000.

Insider Trading History of Stelios Papadopoulos

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Stelios Papadopoulos Trading Performance

GuruFocus tracks the stock performance after each of Stelios Papadopoulos's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Stelios Papadopoulos is 3.37%. GuruFocus also compares Stelios Papadopoulos's trading performance to market benchmark return within the same time period. The performance of stocks bought by Stelios Papadopoulos within 3 months outperforms 3 times out of 9 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Stelios Papadopoulos's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Stelios Papadopoulos

Average Return

Average return per transaction

Outperforming Transactions

2 out of 9 outperforming transactions.

Each transaction is measured over a period and compared to .

	1 Month	3 Months	6 Months	1 Year	2 Years	3 Years
Return(%)	-2.21
Relative Return to S&P 500(%)	-2.87

Stelios Papadopoulos Ownership Network

Ownership Network List of Stelios Papadopoulos

No Data

Ownership Network Relation of Stelios Papadopoulos

Stelios Papadopoulos Owned Company Details

What does Regulus Therapeutics Inc do?

Who are the key executives at Regulus Therapeutics Inc?

Stelios Papadopoulos is the director of Regulus Therapeutics Inc. Other key executives at Regulus Therapeutics Inc include Chief Operating Officer Joseph P Hagan , Sr. VP & General Counsel Christopher Ray Aker , and Chief Financial Officer Crispina Calsada .

Regulus Therapeutics Inc (RGLS) Insider Trades Summary

Over the past 18 months, Stelios Papadopoulos made no insider transaction in Regulus Therapeutics Inc (RGLS). Other recent insider transactions involving Regulus Therapeutics Inc (RGLS) include a net sale of 91,634 shares made by Joseph P Hagan , a net sale of 49,272 shares made by Crispina Calsada , and a net sale of 49,103 shares made by Christopher Ray Aker .

In summary, during the past 3 months, insiders sold 0 shares of Regulus Therapeutics Inc (RGLS) in total and bought 69,610 shares, with a net purchase of 69,610 shares. During the past 18 months, 271,454 shares of Regulus Therapeutics Inc (RGLS) were sold and 73,610 shares were bought by its insiders, resulting in a net sale of 197,844 shares.

Regulus Therapeutics Inc (RGLS)'s detailed insider trading history can be found in Insider Trading Tracker table.

Regulus Therapeutics Inc Insider Transactions

No Available Data

What does Biogen Inc do?

Who are the key executives at Biogen Inc?

Stelios Papadopoulos is the director of Biogen Inc. Other key executives at Biogen Inc include Head of Development Priya Singhal , Head of Research Jane Grogan , and EVP & Human Resources Ginger Gregory .

Biogen Inc (BIIB) Insider Trades Summary

Over the past 18 months, Stelios Papadopoulos made no insider transaction in Biogen Inc (BIIB). Other recent insider transactions involving Biogen Inc (BIIB) include a net sale of 2,167 shares made by Priya Singhal , a net sale of 8,760 shares made by Stephen A Sherwin , and a net purchase of 455 shares made by Eric K Rowinsky .

In summary, during the past 3 months, insiders sold 8,760 shares of Biogen Inc (BIIB) in total and bought 0 shares, with a net sale of 8,760 shares. During the past 18 months, 10,927 shares of Biogen Inc (BIIB) were sold and 455 shares were bought by its insiders, resulting in a net sale of 10,472 shares.

Biogen Inc (BIIB)'s detailed insider trading history can be found in Insider Trading Tracker table.

Biogen Inc Insider Transactions

No Available Data

What does Exelixis Inc do?

Who are the key executives at Exelixis Inc?

Stelios Papadopoulos is the director of Exelixis Inc. Other key executives at Exelixis Inc include Sr. Vice President & Commercial Patrick J. Haley , CSO/EVP Disc & Trans Research Dana Aftab , and EVP and CFO Christopher J. Senner .

Exelixis Inc (EXEL) Insider Trades Summary

Over the past 18 months, Stelios Papadopoulos made no insider transaction in Exelixis Inc (EXEL). Other recent insider transactions involving Exelixis Inc (EXEL) include a net sale of 335,000 shares made by Jeffrey Hessekiel , a net sale of 239,393 shares made by Patrick J. Haley , and a net sale of 241,018 shares made by Dana Aftab .

In summary, during the past 3 months, insiders sold 303,926 shares of Exelixis Inc (EXEL) in total and bought 0 shares, with a net sale of 303,926 shares. During the past 18 months, 1,435,916 shares of Exelixis Inc (EXEL) were sold and 735,409 shares were bought by its insiders, resulting in a net sale of 700,507 shares.

Exelixis Inc (EXEL)'s detailed insider trading history can be found in Insider Trading Tracker table.

Exelixis Inc Insider Transactions

No Available Data

What does BG Medicine Inc do?

Who are the key executives at BG Medicine Inc?

Stelios Papadopoulos is the director of BG Medicine Inc. Other key executives at BG Medicine Inc include director & 10 percent owner Noubar Afeyan , 10 percent owner Flagship Pioneering Inc. , and 10 percent owner Agtc Advisors Fund Lp .

BG Medicine Inc (BGMD) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of BG Medicine Inc (BGMD) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of BG Medicine Inc (BGMD) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

BG Medicine Inc (BGMD)'s detailed insider trading history can be found in Insider Trading Tracker table.

BG Medicine Inc Insider Transactions

No Available Data

What does Genvec Inc do?

Who are the key executives at Genvec Inc?

Stelios Papadopoulos is the director of Genvec Inc. Other key executives at Genvec Inc include director & President and CEO Douglas J Swirsky , 10 percent owner Mmcap International Inc. Spc , and other: See Explanation of Responses Ecor1 Capital Fund Qualified, L.p. .

Genvec Inc (GNVC) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Genvec Inc (GNVC) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Genvec Inc (GNVC) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Genvec Inc (GNVC)'s detailed insider trading history can be found in Insider Trading Tracker table.

Genvec Inc Insider Transactions

No Available Data

What does Eucrates Biomedical Acquisition Corp do?

Who are the key executives at Eucrates Biomedical Acquisition Corp?

Stelios Papadopoulos is the director & 10 percent owner of Eucrates Biomedical Acquisition Corp. Other key executives at Eucrates Biomedical Acquisition Corp include director & 10 percent owner & Chief Executive Officer Parag Saxena , Vice President Atanuu Agarrwal , and Chief Financial Officer Gonzalo Cordova .

Eucrates Biomedical Acquisition Corp (EUCR) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Eucrates Biomedical Acquisition Corp (EUCR) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Eucrates Biomedical Acquisition Corp (EUCR) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Eucrates Biomedical Acquisition Corp (EUCR)'s detailed insider trading history can be found in Insider Trading Tracker table.

Eucrates Biomedical Acquisition Corp Insider Transactions

No Available Data

What does Eucrates Biomedical Acquisition Corp do?

Who are the key executives at Eucrates Biomedical Acquisition Corp?

Eucrates Biomedical Acquisition Corp (EUCRU) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Eucrates Biomedical Acquisition Corp (EUCRU) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Eucrates Biomedical Acquisition Corp (EUCRU) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Eucrates Biomedical Acquisition Corp (EUCRU)'s detailed insider trading history can be found in Insider Trading Tracker table.

Eucrates Biomedical Acquisition Corp Insider Transactions

No Available Data

Stelios Papadopoulos Mailing Address

Above is the net worth, insider trading, and ownership report for Stelios Papadopoulos. Based on the public information released on the U.S. Securities and Exchange Commission (SEC) website, Stelios Papadopoulos's mailing address is: Great Neck Ny 11020.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.